The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within five years.
“Five years after the initial accelerated approval, you should have a definitive answer,” said Dr. Ezekiel Emanuel, a cancer specialist and bioethicist at the University of Pennsylvania who was not involved in the research. “Thousands of people are getting those drugs. That seems a mistake if we don’t know whether they work or not.”
The program was created in 1992 to speed access to HIV drugs. Today, 85% of accelerated approvals go to cancer drugs.
It allows the FDA to grant early approval to drugs that show promising initial results for treating debilitating or fatal diseases. In exchange, drug companies are expected to do rigorous testing and produce better evidence before gaining full approval.
Related articles:
Related suggestion:
Juventus ordered to pay Ronaldo more than $10 million in salary disputeThey cost up to £30. But which posh lip glosses are worth the dosh?Doctors warn about the one skincare mistake that's ageing thousands of women under 30Pakistan says Iran's President Raisi will visit next week despite tensions in the Middle EastChinese leaders attend deliberations at annual legislative sessionChina warns against USUrgent warning over shortages of lifeReal Madrid adapts to Champions League needs: Shock and awe one week, armadillo defense the nextPakistan says Iran's President Raisi will visit next week despite tensions in the Middle EastCongress moving swiftly on bipartisan action to punish Iran after revenge attack on Israel
3.5203s , 5700.921875 kb
Copyright © 2024 Powered by Study: Many cancer drugs unproven 5 years after accelerated approval ,Cultural Currents news portal